Managing Product Supply Risks - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Managing Product Supply Risks
How to use geographic diversification and legacy technology transfers to avoid product shortages.

Pharmaceutical Technology
Volume 36, Issue 4, pp. 102-109

Challenges for mature molecules transfers

Transferring legacy molecules and establishing backup manufacturing capability as part of a geographic diversification strategy to avoid product disruption raises several challenges.

Design objectives. The strategy for how the backup site will be used impacts the engineering design objectives. A company may decide to use both the main and backup site for production, or use the backup site only in an emergency. For example, tax incentives or other financial considerations may favor the use of the primary site. In this instance, the backup site would need to run a limited number of runs as part of the technology transfer to confirm that the product and process operates in a comparable manner to the primary site. The backup site would also need to perform a few runs every 3 to 4 years, or as needed, to maintain the regulatory license. However, in the event of a disruption at the primary manufacturing site, the backup site would need to ramp up very quickly and be able to maintain the product supply to meet product demand. This emergency scenario requires fast run-rates and ramp-up times. In addition, while it may be most efficient to run longer campaigns, the need to meet product demand may necessitate shorter campaigns with more product or host changeovers. Manufacturers should consider these factors when making design decisions, such as equipment sharing or dedication, facility layout, air handling, personnel and material flows, use of clean-in-place equipment, and level of automation. A clear guideline is critical for implementing a design that balances the emergency and regulatory readiness scenarios.

Process characterization. Legacy molecules may have less extensive characterization data than do current molecules that have adopted the design space concept in the QbD approach. The manufacturer can use historical data, however, from both past characterization studies and historical manufacturing experience. Good knowledge management systems, by which the techology transfer teams have easy access to protocols, reports, laboratory notebooks, process monitoring summary reports, campaign summary reports, and annual product reviews are important. The team should learn from deviations and failed lots at the primary site to understand process sensitivities and identify where improved controls are required for robustness. The team may need to make minor changes due to facility constraints. In addition, supplemental characterization studies may be needed to understand the impact of the change on process performance and product quality. These studies should be carefully designed because they could potentially implicate the existing process design at the primary manufacturing site.

Process changes. As mentioned, some process changes may be required due to equipment or facility constraints. The "copy and paste" model (i.e., the identical process scale, process chemistry, and procedures are implemented at the receiving site) can be used to avoid changes that significantly impact the process or product. A rigorous and systematic process for making changes will minimize the risk of failure. First, teams at both the sending and receiving site should identify potential differences or gaps through a "facility fit" or "virtual batch" exercise, in which they review in detail how the process would operate at the backup facility as compared to the primary site. The teams rate the differences based on potential impact to product quality and process (i.e., severity) and the likelihood of occurrence. This risk assessment can take the form of a preliminary hazard analysis (PHA) or failure-mode-and-effects-analysis (FMEA). Once the risks are identified, the team needs to actively manage and mitigate these risks. The team should document any actions taken to reduce the risk level, and review any new risks identified during the technology transfer. Any changes made should have clear reasons and preferential changes should be avoided. Changes based on facility/equipment constraints should be considered against options for additional investment or characterization studies. A key question is when to introduce process improvements. We suggest that the first order of business is to run the secondary site's process as closely as possible to that of the primary manufacturing site. Once the secondary site has been successfully established, process improvements could be made at both sites in tandem, thus avoiding potential process drift problems. When changes are required, teams can leverage generic data, and also generate supplemental characterization data at the bench, including wet testing at scale prior to the cGMP runs.

Meeting current regulatory/validation standards. Another potential challenge in the transfer of legacy molecules is meeting current quality and operating standards at the secondary site, such as expectations for viral clearance and segregation. While the primary facility may have been "grandfathered-in" at the time of the original licensure, today's standards require separation between pre- and post-viral areas and at least one step that provides major viral reduction. Newly licensed sites must also adopt current validation requirements, as published in the FDA's 2011 updated guidance on the lifecycle approach to process validation. While the original validation package may not have included statistical approaches to justify the level of sampling or the number of validation lots, for example, the new validation process must comply.

Establishing statistical process controls. Continual process verification (i.e., process monitoring) and use of statistical process controls (SPC) provide an early indication of process trends and ensure continued control of a robust commercial process. Traditional methods for establishing meaningful statistical control limits, however, typically require greater than 20 runs. If only a few runs are performed every 3 to 4 years at a secondary site, it could take 10 years to establish control limits. Since this is obviously unacceptable to regulatory agencies, an alternative approach is to consider establishing control limits using the combined data set from the primary (main) and secondary (backup) manufacturing sites.

Meeting inspection requirements. At a secondary site, there may be only be a limited window for regulatory inspectors to see the process in operation. The Executive Order issued by the President, however, does require FDA to work with companies to expedite approvals and avoid product shortfalls. It is hoped that some relief may be granted with respect to pre-approval inspections. FDA could adopt, for example, an approach similar to that used by Australia's Therapeutic Goods Adminstration with GMP certification of a facility. This approach would allow the licensure of the facility for different products to be focused on the supplemental product filings related to the site transfer. Regulatory inspection requirements can potentially result in an increase in resources required and hence on the cost and timeline for the successful implementation of the backup facility. Additionally, the team should carefully think through the impact of inspection requirements on the already licensed primary facility.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here